Strota / AUROPHARMA / Quarterly results

Aurobindo Pharma Q1 FY27 Results: Revenue, Profit and Share Price Reaction

Aurobindo Pharma's quarterly results from its filings with NSE, consolidated, with how the share price moved on each announcement.

Q1 FY27 (quarter to 30 Jun 2026): revenue ₹9,150 crore (+16.3% year on year), net profit ₹1,033 crore (+25.2% year on year), EPS ₹17.86. Announced 5 Aug 2026, 9:13 pm IST. The shares fell 1.52% on 6 Aug 2026, 1.56 points worse than the Nifty 50.
Revenue
₹9,150 cr
YoY +16.3% · QoQ +3.4%
Net profit
₹1,033 cr
YoY +25.2% · QoQ +12.1%
EPS (basic)
₹17.86
YoY +25.8%
Share price reaction
-1.5%
6 Aug 2026 · vs Nifty -1.6%

Revenue and net profit by quarter

RevenueNet profit
Q4 FY25 Revenue: ₹8,382 cr Q4 FY25 net profit: ₹903 cr Q4 FY25 Q1 FY26 Revenue: ₹7,868 cr Q1 FY26 net profit: ₹825 cr Q1 FY26 Q2 FY26 Revenue: ₹8,286 cr Q2 FY26 net profit: ₹848 cr Q2 FY26 Q3 FY26 Revenue: ₹8,646 cr Q3 FY26 net profit: ₹910 cr Q3 FY26 Q4 FY26 Revenue: ₹8,853 cr Q4 FY26 net profit: ₹921 cr Q4 FY26 Q1 FY27 Revenue: ₹9,150 cr Q1 FY27 net profit: ₹1,033 cr Q1 FY27

Every quarter

QuarterAnnouncedRevenueYoYNet profitYoYMarginEPSPrice reaction
Q1 FY275 Aug 2026, 9:13 pm IST 9,150+16.3%1,033+25.2% 11.3%17.86 -1.5%
Q4 FY2621 May 2026, 10:12 pm IST 8,853+5.6%921+2.0% 10.4%15.86 -5.4%
Q3 FY269 Feb 2026, 9:10 pm IST 8,646—910— 10.5%15.67 -6.6%
Q2 FY265 Nov 2025, 9:45 pm IST 8,286—848— 10.2%14.61 -0.7%
Q1 FY264 Aug 2025, 8:53 pm IST 7,868—825— 10.5%14.2 -1.0%
Q4 FY2527 May 2025, 12:01 am IST 8,382—903— 10.8%15.56 +0.9%

₹ crore. Consolidated figures; net profit is the share attributable to the company's owners where reported. Margin = net profit ÷ revenue. Year-on-year compares with the same quarter a year earlier.

How AUROPHARMA shares react to results

Across the last 6 results here, the shares rose on 1 and fell on 5. The average move was -2.40%, and the average size of the move either way 2.69%; the biggest was -6.61% after the Q3 FY26 results. In the 2 quarters where profit grew year on year, the shares rose 0 times.

The reaction is the close of the first session that could trade on the news (the announcement day if it came before 3:30 pm, otherwise the next session) against the previous close. A few results don't explain a stock's move; markets also price guidance, commentary and what was expected.

Questions

What were Aurobindo Pharma's Q1 FY27 results?

For the quarter to 30 Jun 2026, Aurobindo Pharma reported revenue of ₹9,150 crore (+16.3% year on year) and net profit of ₹1,033 crore (+25.2%), with basic EPS of ₹17.86.

How did Aurobindo Pharma shares react to the Q1 results?

They fell 1.52% on 6 Aug 2026, the first session that could trade on the results (announced after the close); that was 1.56 points worse than the Nifty 50 that day.

When is Aurobindo Pharma's next results date?

No results date has been announced to NSE yet. Companies give advance notice of the board meeting; the results calendar lists every announced date.

Do Aurobindo Pharma shares usually rise after results?

In the last 6 results here they rose 1 times and fell 5 times, moving 2.69% on average either way.

About this data

From Aurobindo Pharma's Integrated Filing (Financials) XBRL with NSE, which listed companies use for quarterly results since 2025; announcement times are NSE's broadcast times (IST). Share prices are NSE closing prices. See AUROPHARMA stock page for price, open interest and deals, all results declared this week and the results calendar, and AUROPHARMA dividend history.